Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyMVP Health Care Oncology Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentMVP Health CarePolicy N/A

    Cancer Guidance Program-Oncology Medication Coverage

    Customize your policy alerts

    Sign up for all MVP Health Care policy alerts

    Know when MVP Health Care releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy defines clinical criteria used by the Optum Cancer Guidance Program to review prior authorization requests for oncology medications covered under MVP's medical benefit, including chemotherapy, immunotherapy, targeted therapies, oral oncolytics, hematology-supportive agents, and other listed oncology drug therapies.

    Policy Summary
    PayerMVP Health Care
    PolicyCancer Guidance Program-Oncology Medication Coverage
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective Date10/01/2026
    Next Review DateN/A
    Key ActionSubmit prior authorization requests for oncology medications covered under the medical benefit for review using Optum Cancer Guidance Program clinical criteria.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    MedicalPrimary benefit
    2Exception criteria
    1, 2A, 2BAccepted NCCN categories
    Category 3Unproven NCCN category

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    20+Products referenced
    10/01/2026Effective date

    Medical Necessity and Coverage Criteria

    Non-preferred oncology product criteria

    Covered for an oncology indication when ALL of the following are met:

    Non-preferred product medical necessity

    • Qualifying exception: The patient has a history of intolerance or contraindication to one of the preferred products, OR previous documented failure with all preferred products listed for the same requested indication.
    • Provider attestation: The provider attests that the same result is not expected to occur with the non-preferred product.

    General oncology medication medical necessity

    Oncology medications are medically necessary when ANY of the following pathways applies:

    Medical necessity pathways

    • Recognized NCCN support: The use is listed in the NCCN Drugs and Biologics Compendium or Guidelines with a Category of Evidence of 1, 2A, or 2B.NCCN Category 1, 2A, or 2B
    • New-to-market FDA-supported use: For a new-to-market oncology drug, the use is in accordance with an FDA-approved indication.FDA-approved indication
    • Pediatric oncology indication: The patient is under 19 years of age and the medication is used for an oncology indication.Age <19 years

      This pathway applies without regard to NCCN recommendations.

    Medicare Advantage medical-necessity hierarchy

    For eligible Medicare Advantage members, medical necessity is determined according to the applicable Medicare hierarchy:

    Medicare Advantage hierarchy: The applicable Medicare hierarchy includes Medicare Coverage Database National Coverage Determinations, Local Coverage Determinations, and Local Coverage Articles; the Medicare Benefit Policy Manual; the Optum Oncology Medication Policy; and NCCN compendium and guideline evidence.

    Medicare Benefit Policy Manual Chapter 15-50.4.1 allows approval for FDA-labeled use. Chapter 15-50.4.5 allows off-label use of anti-cancer drugs and biologicals when supported by an acceptable compendium or peer-reviewed medical literature with clinically meaningful outcomes.

    Unproven or not medically necessary use

    The following oncology medication use is considered unproven and not medically necessary:

    Unproven or unsupported use: The use is supported only by NCCN Category 3 evidence, or lacks support from an FDA-approved indication, recognized compendium, or acceptable peer-reviewed medical literature.NCCN Category 3 or insufficient accepted evidence

    Oncology medication uses assigned NCCN Category 3 evidence are considered unproven and not medically necessary. Category 3 is not recognized as medically accepted under this policy. Coverage may also require support from an FDA-approved indication, a recognized compendium, or acceptable peer-reviewed medical literature, as applicable.

    Prior Authorization and Provider Requirements

    Prior Authorization

    Submit oncology medications for prior authorization review

    Oncology medications covered under the medical benefit are subject to prior authorization review using the clinical criteria of the Optum Cancer Guidance Program.

    Prior Authorization

    Meet the non-preferred product exception

    Treatment with a non-preferred oncology product is medically necessary only when one of the stated exception criteria is met and the provider attests that the same result is not expected to occur with the non-preferred product.

    • Document a history of intolerance or contraindication to one of the preferred products; or
    • Document previous failure with all preferred products listed for the same requested indication.
    • Attest that the same result is not expected with the non-preferred product.

    Policy Scope and Background

    This policy governs coverage review for oncology medications administered or dispensed under MVP Health Care’s medical benefit. It includes chemotherapy, immunotherapy, targeted therapies, oral oncolytics, leucovorin, gonadotropin-releasing hormone analogs, bone-modifying agents, somatostatin analogs, white blood cell growth factors, red blood cell growth factors, and other supportive oncology drugs.

    Definitions

    FN incidence
    Evidence basisBased on the clinical trial or trials with the highest level of evidence
    Severity gradingGraded according to the Common Terminology Criteria for Adverse Events (CTCAE)
    Criteria sourceNational Cancer Institute (NCI) criteria
    NCCN Category 3
    Evidence categoryNCCN Category 3
    Policy statusConsidered unproven
    Medical necessityNot medically necessary and not recognized as medically accepted under the policy

    Covered Oncology Products and Regimens

    ProductCoverage status
    StimufendCovered
    NyvepriaCovered
    ArmlupegCovered
    NivestymCovered
    ReleukoCovered
    ZarxioCovered
    NeupogenCovered
    GranixCovered
    NypoziCovered
    RyzneutaCovered
    FilkriCovered
    RuxienceCovered
    RituxanCovered
    Rituxan HycelaCovered
    TruximaCovered
    RiabniCovered
    Gemcitabine (Gemzar)Covered
    AvgemsiCovered
    Leucovorin (Wellcovorin)Covered
    Levoleucovorin (Fusilev, Khapzory)Covered
    AranespCovered
    Policy Summary
    PayerMVP Health Care
    PolicyCancer Guidance Program-Oncology Medication Coverage
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective Date10/01/2026
    Next Review DateN/A
    Key ActionSubmit prior authorization requests for oncology medications covered under the medical benefit for review using Optum Cancer Guidance Program clinical criteria.
    SourceLink
    On This Page
    Medical Necessity and Coverage CriteriaPrior Authorization and Provider RequirementsPolicy Scope and BackgroundDefinitionsCovered Oncology Products and Regimens
    Step Therapy

    Follow preferred product sequencing

    Preferred product criteria apply to non-preferred oncology products. A non-preferred product may qualify after intolerance or contraindication to a preferred product, or documented failure of all preferred products for the same indication.

    • Use the applicable preferred product criteria when requesting a non-preferred product.
    • Bone-modifying-agent step therapy is addressed in a separate policy.
    Documentation Required

    Document the exception and provide the attestation

    For a non-preferred product, submit documentation of intolerance or contraindication to a preferred product, or previous documented failure with all preferred products for the same requested indication. The provider must also attest that the same result is not expected with the non-preferred product.

    • Document intolerance or contraindication to one of the preferred products; or
    • Document previous failure with all preferred products listed for the same requested indication.
    • Include the required provider attestation.
    Denial Risk

    Avoid denial without a qualifying exception

    A request for a non-preferred oncology product may not meet medical necessity requirements unless the provider documents a qualifying history of intolerance or contraindication to a preferred product, or documented failure of all preferred products listed for the same indication, and attests that the same result is not expected with the non-preferred product.

    • Qualifying exception: intolerance or contraindication to a preferred product, or failure of all preferred products for the same indication.
    • Required attestation: the same result is not expected with the non-preferred product.
    Denial Risk

    Support the indication with accepted evidence

    Oncology medication use supported only by NCCN Category 3 evidence is considered unproven and not medically necessary. Coverage may also be denied when a new-to-market oncology drug is not used in accordance with an FDA-approved indication or when applicable compendia or accepted peer-reviewed evidence do not support the use.

    • Use NCCN Category 1, 2A, or 2B support when relying on NCCN evidence.
    • For a new-to-market oncology drug, document use in accordance with an FDA-approved indication.
    • For eligible Medicare Advantage members, coverage review follows the applicable Medicare hierarchy.